MIV Therapeutics Officially Named Winner of Prestigious Award for Innovation in Advanced Biomedical Technology; Frost & Sullivan Report Praises MIVT Proprietary Biocompatible Coating Technology for Stents and Other Biomedical Devices.

VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has officially been named winner of Frost & Sullivan's prestigious 2005 Award for Technology Innovation in the Field of Advanced Medical Coatings.

A report by Frost & Sullivan about the award and MIVT's proprietary technology can be viewed at: http://www.trilogy-capital.com/tcp/mivt/frost.html.

The Frost & Sullivan award recognizes MIVT's pioneering work to develop proprietary coating technologies that may enable the production of better, safer vascular stents, medical devices and drug delivery systems. In the award notification, Frost & Sullivan praises MIVT for its development of two distinctive routes for fabricating leading-edge biocompatible coatings for stents. The notification report also explains in detail the substantial competitive advantages of these technologies in the global biomedical marketplace.

MIVT's proprietary technologies have been shown not to trigger a variety of the adverse reactions often associated with currently available polymer-coated coronary stents, including the re-blocking of arteries following angioplasty and thrombosis (blood clotting). MIVT coatings are based on a natural material, Hydroxyapatite (HAp), a component of hard tissue found in human teeth and bone, which enables the surface of metallic stents to virtually mimic the biological "signature" of natural tissue. MIVT believes its innovative technology also has the potential for an array of additional biomedical applications, including dental, hip and bone repair implants.

Each year Frost & Sullivan presents an award to one company or individual whose innovative research is expected to bring significant contributions to the industry. The award criteria recognize the quality and depth of a company's research and development program, as well as the vision and risk-taking that enabled it to undertake such an endeavor.

About Frost & Sullivan

Frost & Sullivan, a respected global independent research and growth consulting firm, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's diversified and unique family of "Smart" drug delivery technologies is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. MIVT is also traded on the Frankfurt Stock Exchange under the ticker symbol MIV. For more information, please visit: http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.